-
HER2-Low Gastric / Gastroesophageal Junction (GEJ) Adenocarcinoma | Primary Research (KOL’s Insight) | Market Intelligence | Epidemiology & Market Forecast-2034
$6,989.00 – $20,967.00Select optionsAccording to Mellalta Meets Analyst’s most recent estimate, the HER2-Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma therapeutics market was worth US$ Billion in 2023 and is predicted to grow at a XX% CAGR to reach US$ Billion by 2034.
-
Head and neck squamous cell carcinoma (LA-HNSCC and Metastatic HNSCC)–Tumour Deck
$11,800.00 – $20,000.00Select optionsThe research study conducted by Mellalta Meets provides insights into the Head and neck squamous cell carcinoma covering both LA-HNSCC and Metastatic HNSCC market dynamics, treatment trends, and key opportunities in the G7 regions. It highlights the need for novel targeted therapies, the potential of biomarker strategies, and the significant market opportunity for drug developers targeting the HNSCC population. The study serves as a comprehensive resource for understanding the current landscape and future prospects of HNSCC treatment.
-
HER2-Low Metastatic Breast Cancer –Tumour Deck
$11,800.00 – $20,000.00Select optionsThe research study conducted by Mellalta Meets provides insights into the HER2-Low Metastatic Breast Cancer market dynamics, treatment trends, and key opportunities in the G7 regions. It highlights the need for novel targeted therapies, the potential of biomarker strategies, and the significant market opportunity for drug developers targeting the HER2-Low population. The study serves as a comprehensive resource for understanding the current landscape and future prospects of HER2-Low mBC treatment.
-
HER2-Low Metastatic Breast Cancer (mBC) | Primary Research (KOL’s Insight) | Market Intelligence | Epidemiology & Market Forecast-2034
$6,989.00 – $20,967.00Select optionsAccording to Mellalta Meets Analyst’s most recent estimate, the HER2-Low Metastatic Breast Cancer therapeutics market was worth US$ Billion in 2023 and is predicted to grow at a XX% CAGR to reach US$ Billion by 2034.
-
Head and neck squamous cell carcinoma (HNSCC)| Primary Research (KOL’s Insight) | Market Intelligence | Epidemiology & Market Forecast-2033
$7,500.00 – $22,500.00Select optionsAccording to Mellalta Meets Analyst’s most recent estimate, the Head and neck squamous cell carcinoma (HNSCC) therapeutics market for HNSCC s was worth US$ Billion in 2023 and is predicted to grow at a 13.9% CAGR to reach US$ 7.5 Billion by 2033.
-
Acute Myeloid Leukemia (AML) –Tumour Slide Deck 2023
$11,800.00 – $20,000.00
$5,900.00 – $10,000.00Select optionsThe research study conducted by Mellalta Meets provides insights into the AML market dynamics, treatment trends, and key opportunities in the G7 regions. It highlights the need for novel targeted therapies, the potential of biomarker strategies, and the significant market opportunity for drug developers targeting the AML population. The study serves as a comprehensive resource for understanding the current landscape and future prospects of AML treatment.
-
Prader-Willi Syndrome (PWS)| Primary Research (KOL’s Insight) | Market Intelligence | Epidemiology & Market Forecast-2032
$6,989.00 – $20,967.00Select optionsThe Prader-Willi Syndrome (PWS) market is hugely contributed by current standard of care (human growth hormone therapy) as there is no cure for PWS. By 2032, the market is expected to change due to the uptake and launch of new novel therapies. In a PWS treatment setting, the current SoC will decline, and the novel emerging drugs will grasp the highest market shares. The sales of the emerging therapies for the treatment of PWS in the study countries (United States, France, Germany, Italy, Spain, United Kingdom and Japan) will experience high growth over the 2018-2032 study period, adding a value estimated at a total market of $ 2.1 billion by 2032.
-
Peripheral T-cell lymphoma (PTCL)| Primary Research (KOL’s Insight) | Competitive Intelligence | Market Analytics & Forecast 2032
$6,989.00 – $20,967.00Select optionsMellalta’s analysts estimate that the United States market is expected to show rapid growth, mainly attributed to, the launch of Adcetris in the front-line setting and expected approval of the potential therapies in the pipeline during the forecast period (2021-2030). Through this, the market size is set to show an extensive jump and grow at a CAGR of 15.3%
-
Obstructive Sleep Apnea (OSA) | Primary Research (KOL’s Insight) | Competitive Intelligence | Market Analytics & Forecast 2032
$6,989.00 – $20,967.00Select optionsGrowth of the Prevalence OSA population will contribute to increasing sales in the OSA therapy market over our forecast period. The increase in the number of patients with obstructive sleep apnea across the globe will be driving the market of OSA. According to a study conducted by the World Health Organization (WHO), the global prevalence of sleep apnea is around 100 million people. In the U.S. alone, the number of people with OSA is around 42 million. One out of five adults in the U.S. has mild OSA, while one out of 15 has moderate to severe OSA. The number of cases with OSA is expected to increase during our forecast period, primarily due to the increasing Prevalence of sleep-related disorders. This is projected to drive the OSA market from 2022 to 2032
-
Neuromyelitis Optica Spectrum Disorder (NMOSD) | Primary Research (KOL’s Insight) | Market Intelligence | Epidemiology & Market Forecast-2032
$6,989.00 – $20,967.00Select optionsWe see great future treatment opportunity for the NMOSD market because of the launch of the emerging therapies like Telitacicept (RC-Pharma), Ravulizumab (Alexion Pharmaceuticals), SHR1459 (Reistone Biopharma) and others potential therapies, providing the global solution for “optic neuritis with spinal cord manifestations and other neurologic disorders associated with the serum aquaporin-4 immunoglobulin G antibodies”. -
Mitochondrial Epilepsy (MIT-E) | Primary Research (KOL’s Insight) | Market Intelligence | Epidemiology & Market Forecast-2032
$6,989.00 – $20,967.00Select optionsThe Mitochondrial epilepsy (MIT-E) therapeutic market is expected to increase at a significant rate during the figure time frame, 2022 to 2032. In 2022, the market is developing at a consistent rate and the market is relied upon to ascend over the projected horizon with the rise in adoption strategies by key market players. The therapy market is expected to experience high growth throughout our study period, increasing from 2018 to 2032. -
Metastatic Renal cell carcinoma (mRCC) | Primary Research (KOL’s Insight) | Market Intelligence | Epidemiology & Market Forecast-2032
$6,989.00 – $20,967.00Select optionsCurrently, tyrosine kinase inhibitors (TKIs) and anti-VEGF antibodies are widely used in first- and second-line treatments for mRCC. Despite the current treatments, there remains the unmet need for early diagnosis and treatment options. Emerging drugs in development like Dovitinib (Allarity Therapeutics) and Savolitinib/ AZD6094 (Astrazeneca), and others will expand the first-line and second-line settings for patients with mRCC and likely to address the current unmet needs for the treatment of mRCC. The upcoming treatment options for mRCC can drive market competition, contributing to budget sustainability and improving patient access to biologic treatments.
Call us today: +1 (304) 470-2225
English
You can use WPML or Polylang and their language switchers in this area.
Market Forecast
Home » Market Forecast
